Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Combination of PSMA-PET/MRI and p2PSA in Early Diagnosis of Prostate Cancer

NCT05822726 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05822726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05822726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Combination of PSMA-PET/MRI and p2PSA in Early Diagnosis of Prostate Cancer
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
October 1, 2022
Completion date
June 30, 2025
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

p2psa, prostate cancer, psma